MLEC
Price
$1.64
Change
-$0.02 (-1.20%)
Updated
Oct 22, 04:49 PM (EDT)
Capitalization
1.2M
56 days until earnings call
Intraday BUY SELL Signals
NIKI
Price
$1.94
Change
+$0.07 (+3.74%)
Updated
Oct 22, 03:46 PM (EDT)
Capitalization
1.52M
Intraday BUY SELL Signals
Interact to see
Advertisement

MLEC vs NIKI

MLEC vs NIKI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MLEC vs. NIKI commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLEC is a Hold and NIKI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MLEC with price predictions
Oct 21, 2026

MLEC's RSI Indicator sits in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLEC advanced for three days, in 102 of 145 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

MLEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MLEC entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.431) is normal, around the industry mean (2.988). P/E Ratio (-0.006) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.011) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MLEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NIKI with price predictions
Oct 21, 2026

NIKI in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 08, 2026

NIKI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 41 of 45 cases where NIKI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIKI advanced for three days, in 158 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NIKI turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

The 50-day moving average for NIKI moved below the 200-day moving average on September 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIKI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for NIKI entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.066) is normal, around the industry mean (2.988). P/E Ratio (-0.984) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NIKI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIKI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NIKI: Fundamental Ratings
NIKI
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MLECNIKI
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 17 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (MLEC: $1.66 vs. NIKI: $1.87)
Brand notoriety: MLEC and NIKI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLEC: 19% vs. NIKI: 10%
Market capitalization -- MLEC: $1.2M vs. NIKI: $1.52M
MLEC [@Biotechnology] is valued at $1.2M. NIKI’s [@Biotechnology] market capitalization is $1.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLEC’s FA Score shows that 1 FA rating(s) are green while NIKI’s FA Score has 1 green FA rating(s).

  • MLEC’s FA Score: 1 green, 4 red.
  • NIKI’s FA Score: 1 green, 4 red.
According to our system of comparison, NIKI is a better buy in the long-term than MLEC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLEC’s TA Score shows that 3 TA indicator(s) are bullish while NIKI’s TA Score has 4 bullish TA indicator(s).

  • MLEC’s TA Score: 3 bullish, 2 bearish.
  • NIKI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MLEC is a better buy in the short-term than NIKI.

Price Growth

MLEC (@Biotechnology) experienced а -11.23% price change this week, while NIKI (@Biotechnology) price change was -15.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.04%. For the same industry, the average monthly price growth was -18.13%, and the average quarterly price growth was -15.32%.

Reported Earning Dates

MLEC is expected to report earnings on Dec 17, 2026.

Industries' Descriptions

@Biotechnology (-1.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
MLEC
Daily Signal:
Gain/Loss:
NIKI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

MLEC and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLEC has been closely correlated with CANF. These tickers have moved in lockstep 89% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLEC jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLEC
1D Price
Change %
MLEC100%
+3.75%
CANF - MLEC
89%
Closely correlated
-0.02%
APVO - MLEC
79%
Closely correlated
-0.93%
GNPX - MLEC
76%
Closely correlated
-3.76%
LNAI - MLEC
64%
Loosely correlated
+0.58%
LONA - MLEC
58%
Loosely correlated
+7.59%
More

NIKI and

Correlation & Price change

A.I.dvisor indicates that over the last year, NIKI has been loosely correlated with HLSQ. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NIKI jumps, then HLSQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NIKI
1D Price
Change %
NIKI100%
-7.88%
HLSQ - NIKI
60%
Loosely correlated
+2.36%
CANF - NIKI
48%
Loosely correlated
-0.02%
APVO - NIKI
46%
Loosely correlated
-0.93%
ICU - NIKI
45%
Loosely correlated
+3.93%
MLEC - NIKI
45%
Loosely correlated
+3.75%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FCHL0.950.05
+5.85%
Fitness Champs Holdings Limited
TYGO0.890.04
+5.11%
Tigo Energy
OCS7.870.38
+5.07%
Oculis Holding AG
PHIN57.17-0.94
-1.62%
PHINIA
BMRN55.21-1.23
-2.18%
BioMarin Pharmaceutical